Sample preparation for peptide aggregation studies
We tried several methods to dissolve the peptide into the buffer medium. We identified difficulties with most of the methods, due to the highly hydrophobic nature of the hVDAC peptides. We were able to attain identical starting concentrations for the all peptides only using one protocol, wherein we employed a TFA mediated transfer process to the desired buffer conditions. Here, all the peptides were prepared by dissolving in neat TFA to achieve a stock peptide concentration of 20 mM. The peptide stock was diluted to achieve final concentrations of 0.2 mM, 0.4 mM and 0.5 mM in 50 mM sodium citrate buffer pH 4.0 (SCB) or 50 mM sodium phosphate buffer pH 7.2 (SPB). The acidity of TFA was neutralized by adding the required volume of 10 N sodium hydroxide in both buffer conditions. Additionally, 0.02% (3 mM) sodium azide was used in all the buffers to suppress bacterial or fungal growth during the 30-day incubation period. We ensured that TFA, NaOH and sodium azide did not interfere in our measurements by checking with the proper controls. To observe the aggregation propensity of the peptide, 12.5 μM of ThT was added to the sample. The final volume of each sample after addition of all the reagents was 200 μl. The buffer blanks were prepared as mentioned above but without peptide addition.
ThT fluorescence measurements of peptide aggregation
ThT fluorescence was measured on a multimode microplate reader (SpectraMax M5, Molecular Devices, LLC). Peptide samples, prepared as outlined above, were incubated in a humidity controlled chamber at 25 °C. The progress of aggregation was monitored every 12 h for 30 days at 25 C. Here, ThT in the peptide samples was excited at a λ ex = 445 nm and the emission spectra were recorded from 465 nm to 530 nm, with an excitation cut-off of 475 nm. The emission maximum of ThT fluorescence was observed at 485 nm and the fluorescence intensity at this wavelength was plotted as a function of time, to observe the peptide aggregation kinetics. All the data were averaged over a minimum of three independent sample preparations in each condition. In specific samples where high peptide aggregation propensity was observed, the data at 465 nm was also plotted and processed.
SEM imaging of peptide aggregates
Scanning electron microscopy (SEM) was performed to identify the morphology of the aggregated peptides. Only those samples containing a peptide concentration of 0.5 mM in SCB were used for imaging. Samples in SPB showed considerable interference from the buffer, and were not processed for SEM. The aggregated samples were diluted considerably for SEM experiments, to observe well-separated images of the peptide aggregates. Samples for imaging were prepared as follows. A 10 μl of the aggregated sample was diluted in 10 μl of SCB. This sample was spotted on aluminum SEM stubs with double-sided carbon tape; samples were air dried at 30 C for 16-18 h. The dried samples were gold coated using a Q150R ES rotarypumped sputter coater instrument from Quorum Technology. The coating was done for 120 s. The gold-coated peptide aggregates were imaged using the Zeiss UltraPlus FE-SEM highresolution field emission scanning electron microscope. An accelerating voltage of 10 kV was used.
Differential interference contrast (DIC) and fluorescence microscopy
The samples that contained 0.5 mM peptide were used for imaging. The sample preparation was as follows. A 5-10 μl aliquot of aggregated peptide was spotted on a glass slide S4 and mounted with a cover slip. Bright field DIC, GFP and DAPI filters were used to acquire the fluorescence images of ThT bound peptides. The images were acquired by using 65X and 100X objective lenses with oil emulsion, on a Leica DM 2500 with high-end CCD Camera DFC365 FX (Leica Microsystems CMS GmBH). The same image processing was applied to all the peptide samples.
Peptide ThT fluorescence data fitting on AmyloFit
The ThT fluorescence data (λ em at 485 nm) was used to understand the molecular mechanism of peptide aggregation and the half-time of peptide aggregation was derived. The fitting was carried out using the AmyloFit tool. 1 The default parameters available with the software were followed. Briefly, the ThT fluorescence intensity at each concentration was normalized between 0 and 1 by using pre-and post-transition data points as baselines. We obtained the best fit of our data to the equation describing a secondary nucleation dominated mechanism for aggregation. 2 We maintained 40-50 basin hoops for the improvement of fitting.
After completion data fitting, half-times (t 1/2 ) were calculated using the instructions provided in AmyloFit. # These peptide sequences are identical in hV1 and hV2 or hV1 and hV3; in these cases, data obtained from the same peptide is used for all three proteins, where appropriate. @ Ionization state and species observed on the ESI-MS is provided in brackets. # These peptide sequences are identical in hV3 and hV1 or hV3 and hV2; in these cases, data obtained from the same peptide is used for all three proteins, where appropriate. @ Ionization state and species observed on the ESI-MS is provided in brackets. *hV3-β7 peptide does not contain the first two N-terminal amino acids (GK). Figure S1 . Mass spectra and analytical RP-HPLC profiles of hV1 peptides and hybrid peptides of hV-β11. Each graph shows the ESI-MS spectrum highlighting the H + and 2H + adducts of the peptide (peptide name provided within each panel). Inset shows the analytical RP-HPLC profile of the crude peptide analyzed using a water-methanol gradient. The hV1-β5 showed inconsistent aggregation in our experiments. Here, β5* denotes the HPLC profile recorded after one month of peptide preparation, where we observe two major peaks corresponding to the expected peptide molecular weight. We suspect that a non-proline mediated cis-trans isomerization exhibited by the peptide may give rise to the observed peaks with different retention times on RP-HPLC. The exact origin of this anomaly is unclear, and is being investigated further. Figure S11. Hydropathy plots for the hVDAC isoforms. Hydropathy plots were calculated using the following well-established scales: Kyte & Doolittle scale (black), 3 Roseman (red), 4 Wolfenden et al., (blue), 5 Eisenberg et al., (green), 6 and Tanford (cyan), 7 scale. The total hydropathy was calculated using a window size of nine residues and the data was normalized between -1 to +1. The region between residues 125 to 155 corresponding to strands β8-β10 in hV1 and hV3 (residues 136 to 166 in hV2) shows a high hydropathy index. Note that hV2 has an additional 11 residues at its N-terminus (termed the N-terminal extension). These residues were not included in the hydropathy index calculation, so as to maintain uniformity across the three human VDAC isoforms. (B) Average hydropathy plots generated from five scales for hV1 (black), hV2 (red) and hV3 (blue), as described in panel A. The numbers above the graph denote the α1 helix and various β-strands (also shown as shaded regions). The average data also shows that the region between residues 125-155 shows a highest hydrophobicity. A single residue substitution in hV2-β11 (R166→Q in hV-β11a) shows significant increase in the peptide aggregation. The R174→K substitution (hV-β11b) in hV2-β11 did not show peptide aggregation. (E and F) The parent sequence of β17 across all VDACs has single amino acid difference at position 245 (Leu in hV1/hV3 → Val in hV2). We observe a marginal difference of ThT intensity in pH 4.0, suggesting that all three peptides show comparable aggregation at this pH condition. On the other hand, we observe a 2-fold increase of ThT intensity in pH 7.2 between hV1/hV3 and hV2. The initial ThT intensities are always higher for the peptides that has greater aggregation tendency and suggests that peptide aggregation nucleation is a very early process. These finding suggests that single amino acid is able to dictate the peptide aggregation and it does not depend upon the total hydrophobicity of the peptide.
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